Medical News Today: Lymphoma/Leukemia News

Tragara Pharmaceuticals, Inc. announced the initiation of a phase I clinical trial of TG02, a unique oral multi-kinase inhibitor, in patients with advanced/refractory hematologic malignancies. Tragara will conduct the study at multiple clinical centers in the United States...

Ann Marie Del Fiacco, a 38-year-old mother of two, owes her life to a stranger who volunteered to be a donor for her life-saving bone marrow transplant. On Sunday, Sept. 12, Del Fiacco will meet her donor, Brad Tacy, for the first time. The meeting will occur at 2 p.m. at Loyola's Cardinal Bernardin Cancer Center, 2160 S. First Ave...

The first study to demonstrate that obesity can directly accelerate the progression of acute lymphoblastic leukemia (ALL) has been conducted at The Saban Research Institute of Childrens Hospital Los Angeles and will be published in Cancer Prevention Research, on October 5, 2010...

Researchers have identified a new target for the treatment of lymphoma and are testing a potential new drug in pet dogs afflicted with the disease. At low doses, the compound, called S-PAC-1, arrested the growth of tumors in three of six dogs tested and induced partial remission in a fourth...

TenX Biopharma, Inc. announced that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients. The trial enrollment was suspended in October 2008 while Genmab (CO:GEN) was seeking a out-license agreement to further develop the compound...

With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children's Research Hospital a prestigious grant to focus on anticancer agent research in children. The five-year, $8.6 million grant is titled "PAAR4Kids Pharmacogenomics of Anticancer Agents Research in Children." "We've been part of the PGRN for 10 years...

Retinoic acid (RA), a natural derivative of vitamin A, is the basis of a number of treatments against cancer. Nevertheless, it has certain disadvantages, such as the possibility of the appearance of retinoic acid syndrome, present in 25% of cases and which can lead to death...

Celgene Corporation (NASDAQ: CELG) announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA)...

Recent studies have shown that acupuncture can help control a number of symptoms and side effects -- such as pain, fatigue, dry mouth, nausea, and vomiting -- associated with a variety of cancers and their treatments...

Millennium: The Takeda Oncology Company announced the publication of an article in the journal Blood describing the novel mechanism of action of MLN4924 through targeted pathway modulation in diffuse large B-cell lymphoma (DLBCL). MLN4924 is a small molecule inhibitor of the NEDD8-Activating Enzyme (NAE), a key component of the protein homeostasis pathway...

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma...

The Swiss health authority Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase...

NewYork-Presbyterian Hospital/Columbia University Medical Center has established a new center devoted to research and treatment of pre-leukemia blood disorders. Known as the Myelodysplastic Syndromes Center, it is one of the largest programs of its kind in the nation. Myelodysplastic syndromes (MDS) are disorders interfering with blood production in the bone marrow...

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010. Chronic lymphocytic leukemia is the most common form of leukemia in the United States...

Janssen-Cilag is disappointed that recommendations from the National Institute for Health and Clinical Excellence (NICE) will limit patient access to Velcade (bortezomib) in newly diagnosed (front-line) multiple myeloma...

In draft guidance published today (26 August 2010) NICE has recommended two treatments for multiple myeloma. Thalidomide (Thalidomide, Celgene) in combination with an alkylating agent and a corticosteroid is recommended for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate...

Today, leukemia patients who have struggled with cancer therapy resistance and intolerance will now have more options thanks to targeted drug therapy. Such new treatment options are due, in part, to a rapid increase in journal and patent publications following the discovery of Gleevec, as reported by Chemical Abstracts Service (CAS), the world's authority for chemical information...

A University of Cincinnati (UC) analysis of 10 years of data from local kidney transplant patients shows that patients removed from a corticosteroid regimen shortly after surgery have better graft survival rates, better survival rates and fewer cardiovascular events than patients kept on the traditional regimen of long-term steroids...

EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) announced that it received a refusal to file letter from the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Ceplene® (histamine dihydrochloride)...

Lawrence Medical Products, a family-owned business conceived to help Autumn Lawrence, diagnosed with infant leukemia in 2005 at seven and a half months old, has announced the launch of the MoveAround™ IV Buggy...